SCHEMBL25399231

SCHEMBL25399231

CC(CO)(NC(=O)O)c1cccc(Cl)c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2B6 P20813 1/20 0.44
SLC6A2 P23975 2/20 0.41
CHRNA1 P02708 1/20 0.41
CHRNG P07510 1/20 0.41
ITGA5 P08648 1/20 0.41
CHRNB1 P11230 1/20 0.41
CHRNB2 P17787 1/20 0.41
CHRNB4 P30926 1/20 0.41
SLC6A4 P31645 1/20 0.41
CHRNA3 P32297 1/20 0.41
CYP2C19 P33261 1/20 0.41
HRH1 P35367 1/20 0.41
CHRNA7 P36544 1/20 0.41
OPRK1 P41145 1/20 0.41
CHRNA4 P43681 1/20 0.41
SLC6A3 Q01959 1/20 0.41
CHRND Q07001 1/20 0.41
KCNH2 Q12809 1/20 0.41
KIF11 P52732 2/20 0.41
ALDH1A1 P00352 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26965566 0.84 PKM (0.40) SLC6A2CHRNA1CHRNGITGA5CHRNB1
SCHEMBL29949477 0.83 CTSL (0.42) CYP2B6SLC6A2CHRNA1CHRNGITGA5
SCHEMBL26257358 0.83 CTSL (0.42) CYP2B6SLC6A2CHRNA1CHRNGITGA5
SCHEMBL25399092 0.83 CTSL (0.42) CYP2B6SLC6A2CHRNA1CHRNGITGA5
SCHEMBL26907235 0.82 CYP3A4 (0.49) CYP2C19SMN1; SMN2CNR2MEN1NPC1
SCHEMBL25408879 0.82 PDE2A (0.45) ALDH1A1SMN1; SMN2MEN1LMNAMAPT
SCHEMBL12496747 0.82 MEN1 (0.41) KIF11ALDH1A1SMN1; SMN2MEN1NPC1
SCHEMBL4438544 0.82 MEN1 (0.41) KIF11ALDH1A1SMN1; SMN2MEN1NPC1
SCHEMBL3447205 0.82 PDE2A (0.45) ALDH1A1SMN1; SMN2MEN1LMNAMAPT
SCHEMBL3677265 0.81 USP36 (0.49) SLC6A2CHRNA1CHRNGITGA5CHRNB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12030856-B2 Potassium channel inhibitors ACESION PHARMA APS (DK) 2024-07-09 US disclosed
US-11945811-B2 Potassium channel inhibitors ACESION PHARMA APS (DK) 2024-04-02 US disclosed
EP-4313973-A1 NOVEL POTASSIUM CHANNEL INHIBITORS Acesion Pharma ApS (DK) 2024-02-07 EP disclosed
US-20230406845-A1 NOVEL POTASSIUM CHANNEL INHIBITORS ACESION PHARMA APS (DK) 2023-12-21 US disclosed
US-20230399301-A1 NOVEL POTASSIUM CHANNEL INHIBITORS ACESION PHARMA APS (DK) 2023-12-14 US disclosed
WO-2023174836-A1 IMIDAZOLE DERIVATIVES AS POTASSIUM CHANNEL INHIBITORS ACESION PHARMA APS (DK) 2023-09-21 WO disclosed
EP-4245753-A1 IMIDAZOLE DERIVATIVES AS POTASSIUM CHANNEL INHIBITORS Acesion Pharma ApS (DK) 2023-09-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12030856-B2 Potassium channel inhibitors KCNJ2, KCNN2, KCNN1 CYP2B6 2363/4885SLC6A2 269/4885CHRNA1 407/4885
US-11945811-B2 Potassium channel inhibitors KCNJ2, KCNN2, KCNN1 CYP2B6 2363/4885SLC6A2 269/4885CHRNA1 407/4885
US-20230406845-A1 NOVEL POTASSIUM CHANNEL INHIBITORS KCNN2, KCNJ2, KCNN1 CYP2B6 2693/4885SLC6A2 291/4885CHRNA1 352/4885
US-20230399301-A1 NOVEL POTASSIUM CHANNEL INHIBITORS KCNN2, KCNJ2, KCNN1 CYP2B6 2693/4885SLC6A2 291/4885CHRNA1 352/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.